FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to an isolated anti-ST2 antibody or antigen-binding fragment thereof. Present invention also relates to an isolated nucleic acid molecule encoding said antibody, an expression vector, a host cell, a fusion polypeptide and a multi-specific molecule comprising said antibody, a viral vector, a method for determining the expression level of ST2 in a sample obtained from a subject, as well as a pharmaceutical composition for treating or alleviating IL33/ST2 mediated diseases and conditions, and a method of treating such diseases.
EFFECT: present invention provides antibodies or antigen-binding fragments thereof that bind to ST2 and are capable of influencing the etiopathogenesis of IL33/ST2-mediated diseases.
25 cl, 13 dwg, 21 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | 2019 |
|
RU2778566C1 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2838943C1 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
